Scottish Enterprise

Green Bioactives is a company focused on sustainable biomanufacturing, specializing in the production of plant biomolecules through a cell-based platform. This innovative approach involves identifying, isolating, and cultivating plant vascular stem cells, allowing for the development of bioactive molecules suitable for various commercial applications. The company's technology aims to provide new solutions for the cosmetic, pharmaceutical, food, and agricultural sectors, addressing the global demand for efficient and sustainable food production. By leveraging natural plant biochemistry, Green Bioactives offers a reliable and economical alternative to traditional methods, promoting sustainability in multiple industries.

Lentitek is a biotechnology company focused on developing gene and gene-modified cell therapies, particularly aimed at treating cancer. The company is dedicated to enhancing the accessibility of innovative cures by increasing the yield of lentiviral vectors, which are critical for gene therapy applications. Lentitek employs a proprietary method that utilizes a novel promoter to significantly boost lentiviral production, potentially increasing yields by tenfold or more. This innovative approach not only improves the efficiency of lentivirus production but also aims to reduce overall production costs for healthcare providers, thereby facilitating broader availability of advanced therapeutic options for patients.

uFraction8 specializes in scalable bioprocessing technology that enhances biomass filtration, separation, and dewatering. The company's innovative approach utilizes microfluidic devices to efficiently process a wide range of microbes, including microalgae, yeast, and bacteria. Unlike traditional methods such as centrifuges, filters, and membranes, uFraction8's technology sorts biomass from culture media without causing harm and without the use of flocculants. This advanced cell separation technology enables industries to achieve higher throughput and reduce costs compared to conventional liquid processing methods. By focusing on industrial-scale applications, uFraction8 provides solutions that streamline operations in various sectors while maintaining efficiency and effectiveness.

Dyneval specializes in portable technology for the analysis of cattle semen quality. Its innovative system measures semen motility in conditions that closely mimic natural environments, providing valuable insights into sperm behavior. By utilizing dynescan data, Dyneval's technology assists in formulating breeding plans and verifying semen quality throughout the supply chain. This approach aims to enhance livestock production, thereby contributing to food security while also addressing environmental concerns by reducing methane emissions. Ultimately, Dyneval's solutions help farmers minimize losses associated with low conception rates.

Concinnity Genetics specializes in enhancing the safety of gene therapies. It employs an artificial intelligence platform to engineer innovative control mechanisms, making gene therapies more predictable, controllable, and safe. This enables researchers to swiftly design and optimize gene therapies for diverse applications.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Neuranics is a company focused on developing advanced magnetic sensors integrated with semiconductor technology for applications in health, fitness, and the metaverse. Their proprietary technology is designed to detect minute magnetic impulses produced by the body's organs, utilizing scalable spintronics sensors. This innovative approach aims to address the limitations of current health monitoring devices and enhance human-machine interfaces. By leveraging magnetic sensing, Neuranics seeks to improve the interaction with the central, peripheral, and autonomic nervous systems, as well as muscles, thereby offering significant advancements for healthcare companies in creating next-generation wearable and implantable devices.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative extracorporeal treatments. The company's core product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures like dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes, particularly for those undergoing long-term dialysis.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, specializing in the modulation of the innate immune system through the development of novel peptide therapeutics. Founded in 2012 and formerly known as Alfacyte Limited, the company focuses on creating hybrid interferons, which are innovative medicines that combine features from various natural interferon subtypes. These hybrid molecules aim to enhance therapeutic efficacy and improve safety across several high-value areas, including cancer, atopic dermatitis, psoriasis, and COVID-19. By advancing this new class of therapeutics, ILC Therapeutics seeks to improve patient outcomes and contribute to the treatment of challenging diseases.

Metacarpal specializes in the development of innovative bionic prosthetic hands designed to enhance the quality of life for individuals with limb differences. Their pioneering technology features fully mechanical prostheses capable of variable grips, allowing users to effortlessly switch between different hand positions for various tasks. This adaptability ensures a secure grip on objects of varying shapes and sizes, complemented by a grip lock feature for added stability. By integrating intuitive control mechanisms reminiscent of body-powered devices, Metacarpal aims to provide users with a natural and responsive experience. In addition to serving individuals in developed regions, the company is committed to supplying prosthetics to underprivileged communities in the developing world, addressing a critical need for accessible assistive technology.

Nandi Proteins Limited is a technology-driven company based in Edinburgh, United Kingdom, focused on enhancing the functional properties of proteins in food manufacturing and nutrition. Established in 2000 and spun out of Heriot Watt University in 2001, the company specializes in patented processes that improve common proteins such as whey, egg, and soy. Nandi Proteins aims to be a leader in denatured protein technology, facilitating growth through direct trading of value-added proteins and strategic licensing agreements with industry partners. Its innovative approach employs a combination of heat, time, and temperature control to modify proteins, enabling food and beverage manufacturers to achieve desirable characteristics and health benefits while efficiently extracting valuable components like enzymes.

Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Nebu-Flow is a manufacturer focused on developing advanced inhaled drug delivery systems for patients with respiratory disorders. The company specializes in innovative technology that controls droplet size to enhance deep lung deposition, facilitating effective drug delivery through inhalation. This technology not only targets existing formulations but also accommodates emerging therapeutics, including biologics, nanomedicines, and vaccines. By enabling injection-free systemic drug delivery, Nebu-Flow aims to improve treatment options for various respiratory, cardiovascular, and central nervous system conditions. The company is also dedicated to minimizing its environmental impact while ensuring its nebulizers remain user-friendly and high-performing.

Glen Clova Scientific is focused on developing a new generation of active biological drugs that aim to create natural antibodies against harmful targets. These innovative drugs are designed to improve the treatment of chronic diseases by minimizing the need for safety monitoring and reducing the frequency of dosing. As a result, patients benefit from a more cost-effective treatment approach, while the company also seeks to address healthcare challenges in markets with limited infrastructure.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.

Beta Bugs is an insect genetics company focused on developing high-performance breeds of Black Soldier Fly for insect farmers. The company's primary mission is to enhance the productivity of the insect protein sector, making it competitive with traditional feed ingredients such as fishmeal and soymeal. To achieve this, Beta Bugs operates a breeding program called HiPer-Fly® and runs an egg production site known as The Multiplier®, supplying its breeds to both UK and international markets. By leveraging biotechnology and breeding techniques, Beta Bugs aims to establish a sustainable protein source that converts food waste into high-quality protein for use in livestock, aquaculture, and pet feed, thereby providing an alternative to conventional feed sources. The company is headquartered at the Easter Bush Campus, collaborating with the Roslin Institute, a leader in animal genetics.

Microplate Dx is a developer of diagnostic technology focused on reducing fatalities from drug-resistant infections. As an award-winning spinout from the University of Strathclyde in Glasgow, the company aims to address the global health challenge of antimicrobial resistance. Microplate Dx's innovative solutions utilize highly sensitive biosensor electrodes, combined with miniaturized hydrogel deposits containing antibiotics specific to the infection being detected. Their medical diagnostic device provides a low-cost and accurate point-of-care alternative, enabling rapid antibiotic prescribing in under one hour. This approach enhances antibiotic stewardship and strives to manage the spread of antimicrobial resistance effectively.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

Carbogenics Ltd is a company based in Edinburgh, United Kingdom, specializing in the development and production of sustainable fertilizers and bio-additives. Established in 2016, Carbogenics has created an innovative process that transforms disposable coffee cups and other non-recyclable paper waste into a carbon-rich material, known as CreChar. This product serves as a carbon additive that enhances biogas production in anaerobic digestion and improves plant growth, ultimately benefiting farmers by increasing crop yields and profitability. In addition to its product offerings, Carbogenics also provides consultancy and analytical services to operators in the anaerobic digestion and wastewater treatment sectors, addressing customer inquiries through various communication channels.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Causeway Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative microRNA therapies for musculoskeletal health. Founded in 2015, the company specializes in treating tendon injuries and disorders in both humans and horses. Its primary products include EquiMiR, designed to treat equine tendinopathy by mimicking natural microRNA with enhanced pharmacological properties, and TenoMiR, which aims to restore key microRNA levels to enhance tendon strength and aid recovery. By targeting the molecular mechanisms that lead to tendinopathy, Causeway Therapeutics seeks to provide effective solutions for managing pain and promoting healing in damaged tendons.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Green Bioactives is a company focused on sustainable biomanufacturing, specializing in the production of plant biomolecules through a cell-based platform. This innovative approach involves identifying, isolating, and cultivating plant vascular stem cells, allowing for the development of bioactive molecules suitable for various commercial applications. The company's technology aims to provide new solutions for the cosmetic, pharmaceutical, food, and agricultural sectors, addressing the global demand for efficient and sustainable food production. By leveraging natural plant biochemistry, Green Bioactives offers a reliable and economical alternative to traditional methods, promoting sustainability in multiple industries.

Roslin Technologies is an ag-tech and food tech company focused on enhancing protein production through innovative biotechnologies. The company specializes in animal stem cell research, having developed perpetually self-renewing, pluripotent stem cells, which are pivotal for the advancement of cultivated meat products for consumers. Roslin's intellectual property and technological platforms are designed to supply these cell lines and related media formulations to the cultivated meat sector. Additionally, the company aims to leverage its stem cell technology to create cell therapies that address incurable diseases in animals, thereby supporting the meat industry in reducing costs and accelerating market entry.

Cytomos Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. Founded in 2011, the company utilizes its patented Dielectric Spectroscopy (CDS) technology to enable label-free cell analysis, providing detailed insights at single-cell resolution. This technology supports various applications in biopharma and cell therapy by facilitating automated, quantitative assessments of samples and enhancing phenotypic drug discovery. Cytomos’ system is designed to scale across all upstream production stages, leveraging machine learning algorithms to analyze extensive data from individual cells, thus improving the efficiency of cell-based diagnostics and enabling researchers to optimize therapeutic dosing.

BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Carcinotech is transforming cancer research through the innovative production of 3D-printed micro-tumours derived from patient biopsies, primary cells, immune cells, and cancer stem cells. This technology facilitates rapid, ethical, and precise drug screening as well as pre-clinical and personalized medicine testing. By leveraging tissue engineering and advanced robotic manufacturing, Carcinotech creates highly predictive, assay-ready tumours that reflect the unique cancer heterogeneity of individual patients. This approach aims to enhance the drug screening process and expedite the development of more effective cancer treatments. Collaborating with global partners, including leading pharmaceutical companies, surgeons, pathologists, and clinicians, Carcinotech is dedicated to advancing oncology drug development and improving treatment outcomes for cancer patients, ultimately increasing their chances of survival.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. The company aims to block the action of the enzyme KMO, which plays a crucial role in regulating systemic inflammation and is implicated in various medical conditions. By providing new therapies that target this key enzyme, Kynos Therapeutics seeks to offer innovative treatments for conditions where there is a significant demand for effective medicines.

Axol Bioscience Ltd., established in 2012 and based in Little Chesterford, United Kingdom, specializes in human cell culture systems for research purposes. The company produces and supplies various types of human cells derived from induced pluripotent stem cells (iPSCs), such as cardiomyocytes, neural stem cells, and astrocytes, along with primary cells like endothelial cells and fibroblasts. Axol also provides essential media, reagents, and growth factors to maintain these cell cultures. Additionally, they offer custom services including iPSC reprogramming, differentiation, genome editing, and cell sourcing tailored to clients' needs. Their products are distributed globally through strategic partners in various countries across Asia, North America, Europe, and internationally.

Rhizocore Technologies specializes in the production of locally-adapted mycorrhizal fungi designed to improve the success of tree planting initiatives. By developing a platform that focuses on enhancing the growth conditions for trees, the company aims to facilitate woodland regeneration and increase overall forest productivity. Its innovative approach addresses the needs of the forestry market, providing effective solutions for sustainable forestry practices.

WellFish Tech is an aquaculture company headquartered in Bridge of Weir, United Kingdom, focused on enhancing fish health monitoring through rapid and non-lethal blood analysis. Founded in 2021 by Brian Quinn, the company aims to improve the sustainability and productivity of the aquaculture industry. WellFish Tech provides health monitoring services that assess fish stock in marine net pens, including smoltification, toxicity assessment, and aquafeed optimization. Their dynamic diagnostic platform is designed to adapt to the evolving needs of the growing aquaculture sector, enabling industrialists to reduce costs, increase productivity, and ultimately enhance profitability.

Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.

uFraction8 specializes in scalable bioprocessing technology that enhances biomass filtration, separation, and dewatering. The company's innovative approach utilizes microfluidic devices to efficiently process a wide range of microbes, including microalgae, yeast, and bacteria. Unlike traditional methods such as centrifuges, filters, and membranes, uFraction8's technology sorts biomass from culture media without causing harm and without the use of flocculants. This advanced cell separation technology enables industries to achieve higher throughput and reduce costs compared to conventional liquid processing methods. By focusing on industrial-scale applications, uFraction8 provides solutions that streamline operations in various sectors while maintaining efficiency and effectiveness.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Dyneval specializes in portable technology for the analysis of cattle semen quality. Its innovative system measures semen motility in conditions that closely mimic natural environments, providing valuable insights into sperm behavior. By utilizing dynescan data, Dyneval's technology assists in formulating breeding plans and verifying semen quality throughout the supply chain. This approach aims to enhance livestock production, thereby contributing to food security while also addressing environmental concerns by reducing methane emissions. Ultimately, Dyneval's solutions help farmers minimize losses associated with low conception rates.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

ILC Therapeutics Ltd is a biotechnology company based in Lanarkshire, United Kingdom, specializing in the modulation of the innate immune system through the development of novel peptide therapeutics. Founded in 2012 and formerly known as Alfacyte Limited, the company focuses on creating hybrid interferons, which are innovative medicines that combine features from various natural interferon subtypes. These hybrid molecules aim to enhance therapeutic efficacy and improve safety across several high-value areas, including cancer, atopic dermatitis, psoriasis, and COVID-19. By advancing this new class of therapeutics, ILC Therapeutics seeks to improve patient outcomes and contribute to the treatment of challenging diseases.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative extracorporeal treatments. The company's core product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures like dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes, particularly for those undergoing long-term dialysis.

BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Asklepios BioPharmaceutical is a biotechnology company focused on developing adeno-associated virus (AAV) gene therapies aimed at treating genetic disorders and rare diseases. Established in 2001 and headquartered in Research Triangle Park, North Carolina, the company possesses proprietary AAV technology and manufacturing capabilities, as well as a robust pipeline of clinical programs. Its pipeline includes clinical-stage therapies for Pompe disease and congestive heart failure, alongside a diverse array of preclinical candidates targeting neuromuscular and central nervous system diseases. Additionally, Asklepios has out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform features Pro10, a proprietary cell line manufacturing process, complemented by an extensive library of AAV capsids and promoters, supporting advancements in genetic medicine through global research collaborations and innovative delivery methods.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.

Manus Neurodynamica Ltd specializes in manufacturing medical diagnostic technologies aimed at identifying and monitoring neuromotor impairments, particularly focusing on Parkinson's disease. Founded in 2008 and based in North Shields, United Kingdom, the company has developed a triage device that supports early diagnostics for this condition. Its innovative technology integrates analytical software to assess a patient's movement parameters by examining subtle limb and hand motions. This capability allows clinicians to quantify fine motor skills and motion features, enhancing the diagnosis and ongoing monitoring of Parkinson's disease. Manus Neurodynamica's solutions are utilized across various sectors, including academic and pharmaceutical research, as well as non-medical applications, contributing to improved efficiency and reduced costs in specialist neuromotor services.

Pneumagen Limited, established in 2015 and based in Saint Andrews, United Kingdom, is focused on developing glycan-targeted carbohydrate-binding modules (CBMs) aimed at treating respiratory tract infections and cancer. This innovative approach seeks to create a universal therapeutic modality that targets respiratory viruses, helping to prevent infections and reduce the need for hospitalization among patients with underlying respiratory conditions. As a spin-out from the University of St Andrews, Pneumagen benefits from access to advanced scientific expertise in glycobiology, positioning itself at the forefront of novel treatment options for these significant health challenges.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, established in 2017. The company specializes in targeted protein degradation technology to develop innovative cancer therapeutics. Amphista's approach focuses on harnessing the body's natural processes to selectively and efficiently degrade disease-causing proteins, aiming to create first-in-class treatments. By advancing novel methodologies in targeted protein degradation, Amphista seeks to improve therapeutic efficacy and modulate protein abundance linked to disease progression, ultimately enhancing patient outcomes in oncology.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Wobble Genomics is a biotechnology firm focused on enhancing the efficiency of RNA and DNA sequencing to facilitate the discovery and detection of nucleic acid biomarkers. The company employs a blend of biochemistry and bioinformatics to achieve unprecedented sensitivity and accuracy in identifying novel biomarkers. By optimizing sampling efficiency during sequencing, Wobble Genomics aims to reduce costs for medical researchers, thereby advancing the field of genomic analysis and improving diagnostic capabilities.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative extracorporeal treatments. The company's core product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures like dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes, particularly for those undergoing long-term dialysis.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

CuanTec Ltd is a Scottish biotechnology company based in Motherwell, specializing in the production of biodegradable plastic films for the food industry. Founded in 2016, CuanTec utilizes a sustainable approach by extracting chitin from waste generated by the fisheries sector, particularly from langoustines sourced from the pollution-free waters of the North Atlantic. This extraction is achieved through a low-energy fermentation process that employs harmless bacteria, resulting in a high-quality product with minimal waste. The company’s compostable and antimicrobial bioplastics serve as an environmentally friendly alternative to conventional packaging, aiming to reduce plastic pollution and food waste while extending the shelf life of fresh food. By employing a circular economy model, CuanTec effectively transforms marine waste into valuable packaging solutions.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, founded in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm focuses on developing innovative diagnostics for the early detection of various cancers, which is crucial for improving treatment outcomes. Dxcover has pioneered the use of infrared spectroscopy combined with artificial intelligence to analyze circulating pan-omic indicators, allowing for the identification of cancer from a simple blood sample. This approach enables same-day diagnosis and patient stratification, facilitating timely interventions. The company has demonstrated strong clinical data supporting the accurate diagnosis of Stage I and Stage II cancers, underscoring its commitment to enhancing survival rates and quality of life for patients.

Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Invizius Ltd., established in 2018 and headquartered in Edinburgh, UK, is a medical technology company specializing in innovative extracorporeal treatments. The company's core product, H-Guard, is an advanced hemocompatible coating designed to prevent foreign body reactions in the blood during procedures like dialysis, cardiopulmonary bypass, and ECMO. By reducing immune system activation, H-Guard aims to minimize cardiovascular complications and improve patient outcomes, particularly for those undergoing long-term dialysis.

Causeway Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, focused on developing innovative microRNA therapies for musculoskeletal health. Founded in 2015, the company specializes in treating tendon injuries and disorders in both humans and horses. Its primary products include EquiMiR, designed to treat equine tendinopathy by mimicking natural microRNA with enhanced pharmacological properties, and TenoMiR, which aims to restore key microRNA levels to enhance tendon strength and aid recovery. By targeting the molecular mechanisms that lead to tendinopathy, Causeway Therapeutics seeks to provide effective solutions for managing pain and promoting healing in damaged tendons.

Enough is a technology spin-out from the University of Strathclyde focused on the development and commercialization of innovative mycoprotein-based food products. The company aims to enhance the sustainability of protein production by integrating its manufacturing processes into existing bio-refinery operations that produce bio-ethanol and animal feed. This approach not only optimizes the production of food but also contributes to a circular economy by utilizing resources efficiently. Enough's products are designed to be environmentally friendly, utilizing less water and generating lower carbon dioxide emissions. The fermentation process employed is zero-waste, resulting in food ingredients that provide all essential amino acids and are high in dietary fiber, making them viable substitutes for meat at a low cost.

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2017. It specializes in researching, developing, and commercializing orally available products for fecal microbiota transplantation. The company creates microbiome-modulating drugs composed of bacterial communities derived from the human gastrointestinal tract, aimed at restoring health and preventing bacterial infections. EnteroBiotix focuses on addressing serious unmet medical needs by offering tailored high-diversity microbial therapeutics, which help physicians prevent and treat debilitating infections and diseases linked to imbalances in gut bacteria.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that leverage mimetics of extra-alveolar lamellar bodies. The company offers Lamellasomes, a synthetic product designed to replicate the functions of lamellar bodies, primarily targeting respiratory diseases such as cystic fibrosis, as well as conditions like dry eye disease and radiotherapy-induced xerostomia. Established in June 2007, Lamellar Biomedical acquired the intellectual property rights to this innovative technology, which aims to improve treatment outcomes through anti-infective properties that enhance antibiotic efficacy and facilitate the delivery of genetic material for pulmonary disease therapies. The company's efforts are directed towards providing transformative solutions for complex and rare respiratory conditions.

Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, focused on developing innovative therapies for inflammatory eye diseases and other autoimmune conditions. The company specializes in soloMERs, which are small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are unique due to their evolutionary lineage, allowing them to bypass the complex patent landscape associated with traditional antibodies. Elasmogen's pipeline includes programs aimed at autoimmune-mediated inflammation, as well as soloMER-drug conjugates designed for enhanced therapeutic delivery. Additionally, the company has developed NDure, a humanized clinical candidate that extends the plasma half-life of fused partner molecules. Elasmogen holds a strong intellectual property position with over 20 granted patents in various regions, supported by strategic partnerships with Almac Discovery Ltd and Merck Inc. Founded in 2014, the company is dedicated to advancing the treatment options available for patients suffering from sight-threatening and inflammatory diseases.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.

MOFgen Ltd is a pioneering company that specializes in the commercialization of metal-organic frameworks (MOFs) for medical and therapeutic applications. Originating as a spin-out from the University of St Andrews, the company leverages patented technology developed by renowned porous material scientist Prof Russell Morris. MOFgen focuses on designing, manufacturing, and formulating MOFs to create innovative solutions for healthcare challenges. Its products include powdery solids with microscopic pores capable of incorporating antibacterial agents, wound healing compounds, and anti-thrombotic substances. These advanced coatings for medical devices aim to enhance patient care by reducing infection rates and minimizing the need for prolonged hospital stays. Through collaboration with various partners, MOFgen is committed to developing tailored solutions for issues such as healthcare-associated infections, bacterial resistance, chronic wounds, and arterial access.

CuanTec Ltd is a Scottish biotechnology company based in Motherwell, specializing in the production of biodegradable plastic films for the food industry. Founded in 2016, CuanTec utilizes a sustainable approach by extracting chitin from waste generated by the fisheries sector, particularly from langoustines sourced from the pollution-free waters of the North Atlantic. This extraction is achieved through a low-energy fermentation process that employs harmless bacteria, resulting in a high-quality product with minimal waste. The company’s compostable and antimicrobial bioplastics serve as an environmentally friendly alternative to conventional packaging, aiming to reduce plastic pollution and food waste while extending the shelf life of fresh food. By employing a circular economy model, CuanTec effectively transforms marine waste into valuable packaging solutions.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, that specializes in the production of biobased materials derived from waste streams in the food processing industry. The company has developed Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. Curran is available in paste, slurry, and powder forms and is suitable for a wide range of applications, including paints, coatings, paper, food products, personal care, home care, cosmetics, concrete, drilling fluids, and composites. CelluComp distributes its products across several regions, including the United Kingdom, Germany, the Netherlands, Poland, France, Spain, Portugal, the Middle East, and the United Arab Emirates. Founded in 2004, CelluComp focuses on creating sustainable, non-hydrocarbon-based materials that enhance product performance while also promoting cost savings for its clients.

Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.

Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, specializing in the development of self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010, the company focuses on a range of applications within spine, trauma, extremities, and biologics. Taragenyx creates innovative therapeutic implants, incorporating bio-passive, bio-active, and bio-regenerative coatings that integrate active pharmaceuticals and biologics into the implant surface. This technology allows for localized release of compounds post-operatively, which can accelerate bone growth, promote faster healing, and reduce the risk of infection and pain. The company’s products are specifically designed to address limb-threatening surgical complications, thereby improving patient outcomes in orthopedic and dental procedures.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development of tunable peptide hydrogels for various applications in cell culture research, including toxicity screening, cancer research, and potential therapeutic uses. Founded in 2012, the company provides hydrogels that mimic the physical and chemical properties of natural tissues, allowing researchers to grow and manipulate cells in a realistic three-dimensional environment. These products are designed to meet the specific requirements of different cell types, offering a viable alternative to traditional animal testing and other 3D cell culture methods. Biogelx's patented hydrogel technologies are marketed in the US, Europe, and Asia, catering to academic institutions, medical researchers, and pharmaceutical companies engaged in drug development and regenerative medicine.

i2Eye Diagnostics Limited, based in Edinburgh, United Kingdom, specializes in developing innovative ophthalmic medical devices that enhance the diagnosis and management of eye and optic nerve disorders. The company's primary product, Saccadic Vector Optokinetic Perimetry (SVOP), measures instinctive responses to light and movement, allowing for accurate visual field testing in pediatric and neuro-ophthalmology contexts. This technology is particularly beneficial for testing children and elderly patients who were previously challenging to assess. i2Eye Diagnostics is a spin-out from the University of Edinburgh and the Edinburgh BioQuarter, and it aims to provide a more accessible and effective approach to visual field analysis by incorporating advanced 3D eye tracking capabilities, which enables patients to move freely during tests without the need for response buttons. Founded in 2010, the company is committed to addressing critical clinical needs in the field of ophthalmology.

Clyde Biosciences, established in 2012 and headquartered in Glasgow, UK, specializes in providing cardiac cell analysis solutions for the pharmaceutical and biotechnology industries, both domestically and internationally. The company's core offerings include cellOPTIQ, an optical action potential assay, and XTENDSR, a solution for measuring drug-induced changes on cardiac sarcoplasmic reticulum function. These solutions enable clients to gain insights into the mechanisms and effects of drug compounds on human cells, aiding in the evaluation of drug toxicity and cardiotoxicity risk during the research and development phase.

Relitect Limited is a biotechnology company based in Motherwell, United Kingdom, founded in 2014. The company focuses on developing a novel assay platform for the label-free electrochemical detection of binding events. This proprietary technology enables the analysis of proteins, small molecules, and nucleic acids, making it applicable in clinical diagnostics and life sciences. Relitect's approach allows for the detection of highly sensitive biomarkers and other analytes in a multiplexed format, which utilizes small sample volumes and minimizes sample interference. By eliminating the potential for labeled reagent cross-talk, Relitect’s technology offers significant advantages for diagnostic and research applications, enhancing the capabilities of clinical diagnostics and life science companies.

DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, specializing in the detection of nucleic acids and single nucleotide polymorphisms (SNPs). Established in 2010 as a spin-out from the University of Edinburgh, the company focuses on commercializing a groundbreaking chemical-based system that differentiates itself from existing enzymatic methods. DestiNA Genomics provides reagents and probes for the detection of nucleic acids and mutations, supporting drug development and profiling in areas such as drug sensitivity, inherited diseases, and infectious diseases. The company aims to launch a completely PCR-free system for nucleic acid analysis, particularly effective for direct detection of micro-RNAs. Additionally, DestiNA Genomics collaborates with trade partners to integrate its technology into various detection platforms, and has established a Spanish subsidiary, DestiNA Genomica SL, to further develop its offerings in Spain with support from a grant aimed at promoting R&D.

MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, specializing in the development of a new class of anti-infective medicines derived from minor groove binder compounds. Established in 2009, the company focuses on creating small molecules with specific antibacterial properties to combat both multi-resistant and susceptible Gram-positive bacteria. One of its key products, MGB-BP-3, is an antibacterial agent designed for the oral treatment of Clostridium difficile-associated disease. MGB Biopharma aims to address the challenges of antibiotic resistance by employing a novel mode of action that targets bacteria lacking inherent resistance mechanisms, offering a promising approach to treating bacterial infections effectively.